-Ritedose is the development partner and manufacturer of Ohtuvayre (ensifentrine)*, the first inhaled product with a novel mechanism of action in more than 20 years for the maintenance treatment of ...

Merck completes $10B acquisition of Verona Pharma, adding Ohtuvayre — the first new inhaled COPD therapy in over 20 years.

Merck & Co. Inc. (NYSE:MRK) is one of the best growth stocks to buy now. On October 7, Merck & Co. announced the completion ...

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from angina, ...

Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases Through this acquisition Merck will add ...

Check this table to make sure you can use your COPD inhalers together Medically reviewed by Sanja Jelic, MD Most people with chronic obstructive pulmonary disease (COPD) use an inhaler every day to ...

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- Aptar Digital Health, part of Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced a strategic ...

International asthma guidelines increasingly support the use of inhaled corticosteroid plus fast-acting β-agonist combinations as both maintenance and reliever therapy, but the only versions on the ...

Italy: A new 15-year analysis has revealed that patients with chronic obstructive pulmonary disease (COPD) who also have ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today ...